Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks.

The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are completely absent in eukaryotic cells.

Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™ [1], including primary cancer cell lines [2], virus producing cells [3] and induced pluripotent stem cells [4], without inducing any permanent alterations. Further, in a recent study, a 2 week treatment with Plasmocin was found to effectively cure mycoplasma contamination in human embryonic stem cells without affecting their stemness and pluripotency nor cell viability [5].